Fannin Innovation Studio

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Fannin Innovation Studio is Houston's most active life sciences development group focused exclusively on commercializing biotech and medtech technologies. Fannin creates and manages start-ups to develop internal and in-licensed assets and programs through clinical proof-of-concept. Fannin has over a dozen active programs, including three in clinical development.

Programs we will share include Pulmotect, developing an anti-COVID-19 therapy in Phase 2 clinical trials; Allterum, developing an anti-IL-7 antibody for the treatment of pediatric T-Cell ALL; ATCG, developing next-generation aptamers (Raptamers) for several indications incuding oncology, opthalmology, and auto-immunity; Encephallay, developing brain-penetrant selective PDE4B inhibitors; Brimstalt, developing targeted anti-cancer therapeutics, and Brevitest, our point-of-care robotic ELISA platform.

For more information, please visit www.fannininnovation.com
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
PUL-042 (Pulmotect)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
12
Speaker
photo
Managing Partner
Fannin Innovation Studio